U.S. Leisure Stock News

Concentra Group Holdings Parent (CON) is in focus after announcing a new medical center at Kansas City Airport in Missouri, expanding access to occupational medicine for employers in a key business and transportation hub. See our latest analysis for Concentra Group Holdings Parent. Concentra Group Holdings Parent's recent Kansas City Airport expansion comes as the stock trades at $31.61, with a 30 day share price return of 4.74% and a strong year to date share price return of 62.85%. The 1...

The quarterly results for West Bancorporation, Inc. ( NASDAQ:WTBA ) were released last week, making it a good time to...

Marqeta (MQ) is drawing attention after recent share price moves, with the stock closing at US$17.07 and showing mixed returns over the past week, month, past 3 months, and year for investors tracking its performance. See our latest analysis for Marqeta. At US$17.07, Marqeta’s recent 1-day share price return of 2.03% comes against a year-to-date share price return that is down 8.03%, while the 1-year total shareholder return has declined 26.30%. This points to short-term momentum within a...

The Denver Post recently launched an investigation into resident care at Colorado’s three largest nursing home chains, including PACS Group, focusing on daily activities and wound treatment at its 19 state facilities. This scrutiny highlights how care quality and regulatory attention can influence perceptions of PACS Group’s operating practices across its broader skilled nursing network. We’ll now examine how this media investigation into resident care standards could affect PACS Group’s...

Emerson Electric (EMR) is in focus after launching new refinery software aimed at automating crude scheduling and product blending, key processes that affect margins, operational efficiency, and responsiveness to shifting refinery conditions. See our latest analysis for Emerson Electric. Emerson Electric’s latest refinery software launch comes after a period of steady share price momentum, with a 7 day share price return of 6.02% and an 8.92% year to date share price return. The 3 year total...

UGI (UGI) has drawn investor attention after recent share price moves, with the stock last closing at $37.33. With mixed short term returns, many investors are reassessing the utility-focused energy group. See our latest analysis for UGI. Recent share price gains over the past month, alongside a relatively modest year to date share price decline of 0.8%, contrast with UGI's 8.0% one year and 63.6% three year total shareholder returns. This suggests sentiment has improved after a softer patch...

EPR Properties recently entered into a Fifth Amended, Restated and Consolidated Credit Agreement, securing a US$1.0 billion senior unsecured revolving credit facility and a US$600.0 million delayed draw term loan facility, while extending maturities, lowering interest costs, and adjusting covenant calculations. An interesting aspect of this agreement is the US$1.0 billion accordion feature and the inclusion of expected forward-equity cash proceeds in asset value tests, which together can...

HCA Healthcare (HCA) has put up another solid quarter, with Q2 2026 revenue of US$20.2 billion and basic EPS of US$7.62, supported by trailing 12 month revenue of US$78.0 billion and EPS of US$30.27 alongside earnings growth of 14.6% year over year. Over recent periods the company has seen revenue move from US$18.6 billion in Q2 2025 to US$20.2 billion in Q2 2026, while quarterly EPS has stepped from US$6.91 to US$7.62 as trailing net profit margin reached 8.8% versus 8.2% a year earlier...

Millicom International Cellular (TIGO) has recently drawn investor attention after a period of mixed share performance, with the stock down 1.8% over the past day but higher over the past month. See our latest analysis for Millicom International Cellular. At a recent share price of US$94.54, Millicom International Cellular has seen short term momentum ease, with the 1 day share price return down 1.78% and the 7 day share price return down 3.86%. However, the 90 day share price return of...

In July 2026, Amalgamated Financial Corp. reported second-quarter 2026 results showing higher net interest income of US$86.06 million and net income of US$34.77 million year over year, while also authorizing a new US$40 million share repurchase program and affirming a quarterly dividend of US$0.17 per share. The combination of stronger profitability and a fresh buyback authorization highlights management’s confidence in the bank’s capital position and ongoing earnings power, alongside a...

Kyndryl Holdings (KD) shares are in focus after the company and Aptiv agreed to work together, pairing Kyndryl’s advisory and managed services with Aptiv’s Wind River software across mission-critical environments. See our latest analysis for Kyndryl Holdings. The latest Aptiv collaboration arrives at a time when Kyndryl Holdings’ share price has risen 6.45% over the past 30 days but remains under pressure, with the share price return down 52.73% year to date and the 1 year total shareholder...

Nasdaq, Inc. ( NASDAQ:NDAQ ) defied analyst predictions to release its quarterly results, which were ahead of market...

As you might know, Shore Bancshares, Inc. ( NASDAQ:SHBI ) just kicked off its latest second-quarter results with some...

RB Global (RBA) drew fresh investor attention after its Board of Directors declared a regular quarterly cash dividend of US$0.33 per share, payable in September to shareholders of record in late August. See our latest analysis for RB Global. At a share price of US$111.59, RB Global has delivered an 8.04% year to date share price return. Its 1 year total shareholder return of 3.47% contrasts with a much stronger 3 year total shareholder return of about 80%, suggesting longer term momentum...

Some Marsh & McLennan Companies, Inc. ( NYSE:MRSH ) shareholders may be a little concerned to see that the Independent...

NovoCure recently reported its strongest-ever second quarter, with net revenue rising to US$183.58 million, a smaller net loss of US$15.66 million, and an upgraded 2026 net revenue outlook to US$710 million–US$725 million. The company also secured a CE Mark for its Optune Pax device in locally advanced pancreatic cancer and is anticipating FDA premarket approval for TTFields in brain metastases from non-small cell lung cancer, underscoring how expanding indications could reshape its...

Recently, brokers have upgraded their ratings on The Chemours Company, which now carries a Zacks Rank #1, backed by forecasts for stronger earnings growth into 2026. This shift in analyst sentiment highlights growing confidence in Chemours’ earnings outlook, potentially influencing how investors judge its longer-term profit recovery story. Next, we’ll examine how this uptick in broker ratings could reshape Chemours’ investment narrative around earnings quality and future growth. The latest...

Q2 Earnings Anticipation and Dividend Move Put Colgate-Palmolive in Focus Colgate-Palmolive (CL) is in the spotlight as investors look ahead to Q2 results, with attention on international performance, organic sales trends, and a higher quarterly dividend of US$0.53 per share. See our latest analysis for Colgate-Palmolive. At a share price of US$90.75, Colgate-Palmolive has had a mixed near term patch, with the share price return declining 2.4% over the past week but rising 7.8% over 90 days...

Tenet Healthcare (THC) is back on investors' radar after second quarter 2026 earnings and new full year guidance pointed to stronger profitability, higher revenue expectations and a larger share repurchase program. See our latest analysis for Tenet Healthcare. The latest earnings and guidance reset have clearly shifted sentiment, with Tenet Healthcare’s share price up 17.17% on the day and posting a 25.69% 3 month share price return. The 1 year total shareholder return of 52.40% and 3 year...

Edwards Lifesciences stock sits in an interesting spot for investors right now, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting the current price is roughly in line with fair value, while the broader valuation checks and recent 5 year share price record do not point to a clear bargain. Over the past 5 years, Edwards Lifesciences shares have declined 26.4%, which puts more focus on whether today’s price now fairly reflects the company’s prospects. Recent optimism...

TransUnion (TRU) has drawn fresh attention after introducing TruVision Alternative Credit Attributes (ACA 2.0) into its mortgage credit reports. The company is using FactorTrust data to broaden lender insight beyond traditional credit files and earlier in the loan funnel. See our latest analysis for TransUnion. Against this product update backdrop, TransUnion's share price has moved to $76.51, with a 30 day share price return of 8.76% and a 90 day gain of 7.47%. However, the 1 year total...

Why Charles Schwab Stock Is Back in Focus After Q2 Results Charles Schwab (SCHW) is drawing attention after reporting second quarter net income of US$2.8b and basic earnings per share of US$1.55, both higher than the figures reported a year earlier. See our latest analysis for Charles Schwab. Alongside the stronger Q2 and first half results and fresh dividend declarations, Charles Schwab’s share price has climbed to US$101.97, with a 30 day share price return of 12.46% and a 1 year total...

Earlier this month, Stoke Therapeutics appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, adding more than 25 years of R&D and rare disease drug development leadership to its senior team. His background in advancing genetic and RNA-based medicines, including experience with mRNA technologies and antisense platforms, could be particularly relevant to Stoke’s antisense oligonucleotide programs targeting severe genetic diseases. Next, we’ll examine how bringing in a Chief Scientific...

Citigroup stock has logged a very large 207.6% return over the past three years, yet current checks suggest it still trades at a discount, with both the Excess Returns intrinsic value estimate and earnings multiples pointing to an undervalued profile rather than a stretched one. Over the past three years, Citigroup has delivered a 207.6% return, which puts the current share price in focus against what the underlying value signals suggest. Recent progress on Citi's multi year transformation,...